Synthon opens state-of-the-art laboratory for biotechnology

“With this new building, Synthon has significantly expanded its scientific infrastructure, putting us in an excellent position to fulfill our far-reaching ambitions in the field of biotechnological products,” says Rudy Mareel, CEO. “Our high-quality generic medicines and the new building allow us to continue developing as complete a portfolio as possible for our most important therapeutic areas: Multiple Sclerosis (MS) and Oncology.”

The new building will be home to around 130 R&D staff, and the 6,850 m2 surface area includes two floors with 1000 m2 of laboratory space. Thanks to a unique collaboration between the parties involved, the building was erected in a record time of less than a year. The work was done with a specific construction team, a fixed budget and complete financial transparency. Construction even started during the design stage and the entire process was conducted according to Lean Construction principles, resulting in enormous efficiency savings.